Last updated on September 2018

Cytoreductive Prostatectomy Versus Cytoreductive Prostate Irradiation as a Local Treatment Option for Metastatic Prostate Cancer: a Multicentric Feasibility Trial

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Prostate Cancer Metastatic
  • Age: Between 18 - 100 Years
  • Gender: Male

Inclusion Criteria:

  • Male 18y
  • Histologically proven PC
  • Newly diagnosed metastatic PC as assessed by standard imaging (CT and bone scintigraphy)
  • ECOG 0-1 (2 if related to local PC symptoms)
  • Eligible for local treatment
  • Written informed consent and able and willing to comply with protocol requirements

Exclusion Criteria:

  • Previous systemic treatment for PC except ADT started within 3 months before randomization
  • Previous radiotherapy to the pelvis interfering with prostate irradiation
  • Previous surgery in the pelvis interfering with radical prostatectomy
  • Symptoms related to metastatic lesions, persisting for at least 2 weeks after initiation of ADT
  • Metastatic brain disease, leptomeningeal disease or imminent spinal cord compression
  • Previous or current malignant disease which is likely to interfere with LoMP II treatment or assessment
  • Psychological disorder intervening with understanding the information or the informed consent

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.